Early Rhythm Control in AF: Where Do We Stand?

OVERVIEW

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Data show that mortality associated with AF is highest in the first year following initial diagnosis. Thus, the first months following diagnosis may be the time when AF exerts many detrimental effects in patients. Yet the question remains as to whether early and comprehensive rhythm control therapy has the potential to prevent adverse outcomes in patients with AF. In this CME-certified live discussion, Drs Jonathan Piccini, John Camm, and Carina Blomström-Lundqvist will review recent clinical and real-world data on early rhythm control in AF, and discuss the clinical implications of new data and guidelines on the choice of rhythm control therapy.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Recent data on the use of antiarrhythmic drug (AAD) therapy to improve rhythm control in patients with AF [ITEM]Recent clinical guidelines on the use of AAD therapy in patients with AF [/LIST]Have greater competence related to [LIST] [ITEM]Application of the latest data and clinical guidelines on the use of AAD therapy in patients with AF[/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [MEDSCAPE] [JALOGO]

[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.